RT Journal Article
SR Electronic
T1 Prospective population-based observational study to estimate the incidence of T2DM in a metropolitan population in the north of Madrid (Spain) and to determine the effect of baseline glycaemic status through an explanatory Cox model. SPRINDIAP-1 study (Secondary PRevention of INcident DIAbetes in patients with Prediabetes)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.16.23291494
DO 10.1101/2023.06.16.23291494
A1 Iriarte-Campo, V
A1 de Burgos-Lunar, C
A1 Mostaza, J
A1 Lahoz, C
A1 Cárdenas-Valladolid, J
A1 Gómez-Campelo, P
A1 Taulero-Escalera, B
A1 San-Andrés-Rebollo, FJ
A1 Rodriguez-Artalejo, F
A1 Salinero-Fort, MA
A1 SPREDIA-2 Group
YR 2023
UL http://medrxiv.org/content/early/2023/06/19/2023.06.16.23291494.abstract
AB Background T2DM (Type 2 Diabetes mellitus) is preceded by basal glycaemic states (BGS) such as normoglycaemia (NG) or pre-T2DM, including impaired fasting glucose (IFG); impaired glucose tolerance (IGT) or both (IFG-IGT). A better understanding of the role of pre-T2DM in the progression to T2DM may help in the prevention of T2DM in patients with pre-T2DM.Methods Population-based cohort study to estimate the incidence of T2DM according to BGS and to study the adjusted effect of BGS on progression to T2DM using a Cox model (main model (MM) with reference category NG and sensitivity analysis (SA) in patients with pre-T2DM and reference IFG).Results 1,209 patients aged 45-74 years (median follow-up=7.26 years). The crude T2DM incidence rate for the whole population was 11.21 per 1000 person-years (95%CI=9.09-13.68), 5.60 (95%CI=3.55-8.41) in patients with NG and 16.28 (95%CI=12.78-20.43) in patients with preT2DM. In both models, the significant variables showing risk of progression to T2DM were IGT BGS (MM: Hazard ratio HR=4.30; 95%CI=1.96-9.44; AS: HR=2.66, 95%CI=1.28-5.56) and IFG-IGT (MM: HR=3.71, 95%CI=1.97-6.99; AS: HR=2.45, 95%CI=1.41-4.23), and obesity (MM: HR=2.36, 95%CI=1.15-4.83; AS: HR=2.97, 95%CI=1.18-7.45). Being on diuretic treatment was a protective factor (MM: HR=0.47 CI95%=0.23-0.96; SA: HR=0.41, CI95%=0.19-0.92), as was, in SA only, self-perceived health status in the categories of: Very good (HR: 0.19, CI95%=0.06-0.67); Good (HR: 0.35, CI95%=0.13-0.96) and Fair (HR: 0.31, CI95%=0.11-0.93).Conclusions Our T2DM incidence rates are in line with other Spanish studies. In people with NG or preT2DM, EBG (IGT and IFG-IGT) and obesity increase the risk of progression to T2DM and being on diuretics is a protective factor as is fair to very good self-perceived health in patients with preT2DM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe SPRINDIAP-1 study is funded by European Regional Development Fund projects PI15/00259 and PI18/01025.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PI1500259 project (entitled Cohort study on cardiovascular morbidity and mortality in subjects with known and unknown T2 diabetes, pre-diabetes and normoglycaemia) was approved in 2 October 2015 by the Research Ethics Committee of the Hospital Universitario Ramon y Cajal (Madrid). This approval included future studies in which its patients would be followed up. Specifically, the SPRINDIAP-1 study follows up patients who had prediabetes at baseline in the PI1500259 project. Since SPRINDIAP-1 clinical data have been obtained from the patients' PC-EHR (secondary data), our study was exempt from obtaining the signature of a new informed consent form from patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDatasets generated and/or analysed during the current study are available from the corresponding author on reasonable request